Clinical Trial

A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of combination broadly neutralizing antibodies (bNAbs), to induce HIV-1 control during analytic treatment interruption (ATI).
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-15; most recent amendment 2026-06-12.
Trial Details
NCT Number NCT06987318
Lead Sponsor National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators: Monogram Biosciences
Conditions HIV-1-infection
Enrollment 40 participants
Start Date 2026-12-01
Primary Completion 2027-08-29 (estimated)
Study Completion 2028-05-07 (estimated)
Updated on ClinicalTrials.gov 2026-06-15